Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. announced that data from the randomized withdrawal period of Study C602 of DCCR extended-release tablets in Prader-Willi Syndrome will be featured in an oral presentation...

Related Keywords

Massachusetts ,United States ,Boston , ,Soleno Therapeutics Inc ,Prader Willi Syndrome Association United States ,Meeting Of The Endocrine Society ,Foundation For Prader Willi Research ,Soleno Therapeutics ,Prader Willi Syndrome ,Annual Meeting ,Endocrine Society ,Prader Willi Research ,Orphan Drug Designation ,Fast Track ,Breakthrough Designations ,